96 related articles for article (PubMed ID: 9388525)
1. [Investigation of doxorubicin cardiotoxicity by echocardiogram and the appropriate method of using doxorubicin].
Okada Y; Horikawa K; Makino H; Sano M
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2137-41. PubMed ID: 9388525
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
Villani F; Meazza R; Materazzo C
Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
[TBL] [Abstract][Full Text] [Related]
3. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography.
Cottin Y; Touzery C; Dalloz F; Coudert B; Toubeau M; Riedinger A; Louis P; Wolf JE; Brunotte F
Clin Cardiol; 1998 Sep; 21(9):665-70. PubMed ID: 9755384
[TBL] [Abstract][Full Text] [Related]
4. [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
Okada Y; Horikawa K; Sano M
Gan To Kagaku Ryoho; 1997 Mar; 24(5):585-9. PubMed ID: 9087292
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
8. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
9. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
[No Abstract] [Full Text] [Related]
10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
11. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
Bernardi D; Errante D; Stefani M; Salvagno L
Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
[No Abstract] [Full Text] [Related]
12. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
13. Late cardiotoxicity after treatment for a malignant bone tumor.
Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
[TBL] [Abstract][Full Text] [Related]
14. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
Morgan GW; McIlveen BM; Freedman A; Murray IP
Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
[TBL] [Abstract][Full Text] [Related]
15. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C.
Villani F; Comazzi R; Lacaita G; Guindani A; Genitoni V; Volonterio A; Brambilla MC
Med Oncol Tumor Pharmacother; 1985; 2(2):93-7. PubMed ID: 3932789
[TBL] [Abstract][Full Text] [Related]
16. [Doxorubicin-induced myocardial damage in elderly patients with hematologic malignancies].
Niitsu N; Kato M; Shikoshi K; Umeda M
Nihon Ronen Igakkai Zasshi; 1997 Jan; 34(1):38-42. PubMed ID: 9077103
[TBL] [Abstract][Full Text] [Related]
17. [Acute cardiogenic postoperative edema after doxorubicin (adriamycin) chemotherapy].
Boulay G; Debaene B
Ann Fr Anesth Reanim; 1998; 17(1):43-6. PubMed ID: 9750682
[TBL] [Abstract][Full Text] [Related]
18. Short-term and long-term models of doxorubicin-induced cardiomyopathy in rats: A comparison of functional and histopathological changes.
O'Connell JL; Romano MM; Campos Pulici EC; Carvalho EE; de Souza FR; Tanaka DM; Maciel BC; Salgado HC; Fazan-Júnior R; Rossi MA; Simões MV
Exp Toxicol Pathol; 2017 Apr; 69(4):213-219. PubMed ID: 28153388
[TBL] [Abstract][Full Text] [Related]
19. Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy.
Takano H; Ozawa H; Kobayashi I; Hamaoka S; Nakajima J; Nakamura T; Sato K; Kimura H; Naito A; Obata S; Koizumi K; Tamura K
J Cardiol; 1996 Feb; 27(2):49-55. PubMed ID: 8919183
[TBL] [Abstract][Full Text] [Related]
20. Heart failure in a breast cancer survivor.
Moore S
Oncol Nurs Forum; 2012 Mar; 39(2):147-50. PubMed ID: 22374488
[No Abstract] [Full Text] [Related]
[Next] [New Search]
